Literature DB >> 16565968

Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients.

Maha Boktour1, Hend Hanna, Shoaib Ansari, Boulos Bahna, Ray Hachem, Jeffrey Tarrand, Kenneth Rolston, Amar Safdar, Issam Raad.   

Abstract

BACKGROUND: Stenotrophomonas maltophilia bacteremia is frequently found in cancer patients. This study attempted to determine how often the catheters were the source of this infection and the risk factors associated with catheter-related bacteremias.
METHODS: The microbiology records were retrospectively reviewed of all cancer patients having S. maltophilia bacteremia and indwelling central venous catheters seen between January 1998 and January 2004. In a multivariate analysis the patients' clinical characteristics, antimicrobial therapy, outcome, and source of bacteremia that were significantly associated with definite catheter-related S. maltophilia bacteremia as opposed to secondary bacteremia were identified.
RESULTS: A total of 217 bacteremias were identified in 207 patients: 159 (73%) were primary catheter-related (53 definite, 89 probable, and 17 possible), 11 (5%) were primary noncatheter-related, and 47 (22%) were secondary. Multivariate analysis showed the following factors to be independently associated with definite catheter-related bacteremias: 1) polymicrobial bacteremia (odds ratio [OR], 7.6; 95% confidence interval [95% CI], 1.3-45.5); 2) no prior intensive care unit admission (OR, 0.06; 95% CI, 0.005-0.578); and 3) nonneutropenic status at onset (OR, 0.07; 95% CI, 0.013-0.419). The response rate to appropriate antibiotics and catheter removal was 95% in the patients with definite catheter-related bloodstream infections, compared with only 56% in the patients with secondary bacteremias (P = .001).
CONCLUSIONS: The majority of the S. maltophilia bacteremias occurring in cancer patients with indwelling central venous catheters appear to be catheter-related and are often polymicrobial. Catheter-related S. maltophilia bacteremias occurred more frequently in noncritically ill, nonneutropenic patients, and prompt removal of the catheter was found to be associated with a better prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16565968     DOI: 10.1002/cncr.21846

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Stenotrophomonas maltophilia bacteremia and pneumonia at a tertiary-care oncology center: a review of 16 years.

Authors:  Consuelo Velázquez-Acosta; Sugehily Zarco-Márquez; Mari Carmen Jiménez-Andrade; Patricia Volkow-Fernández; Patricia Cornejo-Juárez
Journal:  Support Care Cancer       Date:  2018-01-07       Impact factor: 3.603

2.  Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients.

Authors:  D Averbuch; E Horwitz; J Strahilevitz; P Stepensky; N Goldschmidt; M E Gatt; M Y Shapira; I B Resnick; D Engelhard
Journal:  Infection       Date:  2013-05-08       Impact factor: 3.553

3.  Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients.

Authors:  Hayati Demiraslan; Mustafa Sevim; Çiğdem Pala; Süleyman Durmaz; Veli Berk; Leylagül Kaynar; Gökhan Metan
Journal:  Int J Hematol       Date:  2013-02-22       Impact factor: 2.490

4.  In vivo biocompatibility and in vitro efficacy of antimicrobial gendine-coated central catheters.

Authors:  Mohamed A Jamal; Ray Y Hachem; Joel Rosenblatt; Mark J McArthur; Edd Felix; Ying Jiang; Ramesh C Tailor; Issam Raad
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

5.  Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.

Authors:  Ji-Yong Lee; Cheol-In Kang; Jae-Hoon Ko; Woo Joo Lee; Hye-Ri Seok; Ga Eun Park; Sun Young Cho; Young Eun Ha; Doo Ryeon Chung; Nam Yong Lee; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

6.  Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia.

Authors:  J I Garcia Paez; F M Tengan; A A Barone; A S Levin; S F Costa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-16       Impact factor: 3.267

7.  Prevention of biofilm colonization by Gram-negative bacteria on minocycline-rifampin-impregnated catheters sequentially coated with chlorhexidine.

Authors:  Mohamed A Jamal; Joel S Rosenblatt; Ray Y Hachem; Jiang Ying; Egbert Pravinkumar; Joseph L Nates; Anne-Marie P Chaftari; Issam I Raad
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

Review 8.  The versatility and adaptation of bacteria from the genus Stenotrophomonas.

Authors:  Robert P Ryan; Sebastien Monchy; Massimiliano Cardinale; Safiyh Taghavi; Lisa Crossman; Matthew B Avison; Gabriele Berg; Daniel van der Lelie; J Maxwell Dow
Journal:  Nat Rev Microbiol       Date:  2009-07       Impact factor: 60.633

9.  Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy.

Authors:  Samuel L Aitken; Pranoti V Sahasrabhojane; Dimitrios P Kontoyiannis; Tor C Savidge; Cesar A Arias; Nadim J Ajami; Samuel A Shelburne; Jessica R Galloway-Peña
Journal:  Clin Infect Dis       Date:  2021-05-04       Impact factor: 9.079

10.  Treatment refractory Stenotrophomonas maltophilia bacteraemia and pneumonia in a COVID-19-positive patient.

Authors:  Zachary Pek; Maria Gabriela Cabanilla; Shozab Ahmed
Journal:  BMJ Case Rep       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.